Immunovant Enterprise Value Over E B I T D A from 2010 to 2024
| IMVT Stock | USD 26.54 0.37 1.41% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (13.82) | Current Value (5.03) | Quarterly Volatility 2.83102594 |
Check Immunovant financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunovant's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 34.8 M or Other Operating Expenses of 296.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.8 K. Immunovant financial statements analysis is a perfect complement when working with Immunovant Valuation or Volatility modules.
Immunovant | Enterprise Value Over E B I T D A |
Latest Immunovant's Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Immunovant over the last few years. It is Immunovant's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunovant's overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Immunovant Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (8.02) | |
| Coefficient Of Variation | (35.31) | |
| Mean Deviation | 1.86 | |
| Median | (8.76) | |
| Standard Deviation | 2.83 | |
| Sample Variance | 8.01 | |
| Range | 13.0908 | |
| R-Value | 0.21 | |
| Mean Square Error | 8.26 | |
| R-Squared | 0.04 | |
| Significance | 0.46 | |
| Slope | 0.13 | |
| Total Sum of Squares | 112.21 |
Immunovant Enterprise Value Over E B I T D A History
About Immunovant Financial Statements
Immunovant shareholders use historical fundamental indicators, such as Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Immunovant investors may analyze each financial statement separately, they are all interrelated. The changes in Immunovant's assets and liabilities, for example, are also reflected in the revenues and expenses on on Immunovant's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (13.82) | (5.03) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.